title: A response to "Comment on 'A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis'".
authors.affiliation: Department of Dermatology, Eastern Virginia Medical School, Norfolk. Electronic address: rpariser@gmail.com.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Pariser
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D012507:Sarcoidosis / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized